**Recommendations for participation in competitive and leisure time sport in athletes**

**with cardiomyopathies, myocarditis and pericarditis**

**Position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC).**

Antonio Pelliccia, MD, FESC, Erik Ekker Solberg MD, Michael Papadakis, MD, FESC, Paolo Emilio Adami, MD, FESC, Alessandro Biffi, MD, FESC, Stefano Caselli, MD, FESC, Andre La Gerche, MD, FESC, Josef Niebauer, MD, Axel Pressler, MD, Christian Schmied, MD, Luis Serratosa, MD, PhD, Martin Halle, MD, FESC, Frank Van Buuren, MD, Mats Borjesson, MD, PhD, FESC, Francois Carré, MD, Nicole Panhuyzen-Goedkoop, MD, Hein Heidbuchel, MD, PhD, FESC, Iacopo Olivotto, MD, Domenico Corrado, MD, PhD, FESC, Gianfranco Sinagra, MD, FESC, and Sanjay Sharma, MD, FESC.

Address for correspondence:

Antonio Pelliccia

Institute of Sport Medicine and Science

Largo Piero Gabrielli 1.

Rome 00197.

mail: ant.pelliccia@libero.it

**List of contents**

Abstract

Preamble

Diagnosis of cardiomyopathy in athletes

Shared Decision Making Process

Hypertrophic Cardiomyopathy (HCM): evaluation and risk stratification

 Genetic Carriers of HCM

Dilated Cardiomyopathy (DCM): evaluation and risk stratification

Genetic Carriers of DCM

Left Ventricular Non-Compaction Cardiomyopathy (LVNC): evaluation and risk stratification

Arrhythmogenic (Right Ventricular) Cardiomyopathy (AC): evaluation and risk stratification Genetic Carriers of AC

Isolated Abnormal ECGs

Athletes with cardiomyopathy and implanted cardioverter defibrillator (ICD)

Prescription for Leisure-time Physical and Sport Activity in Patients with cardiomyopathy.

**Myocarditis: evaluation and risk stratification**

Pericarditis: **evaluation and risk stratification**

**References**

Figure 1.

**Abstract**

Myocardial diseases are associated with an increased risk of potentially fatal cardiac arrhythmias and sudden cardiac death/arrest (SCD/CA) during exercise, including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), left ventricular non-compaction (LVNC), arrhythmogenic cardiomyopathy (AC), and myo-pericarditis.

Practicing cardiologists and sport physicians are required to identify high-risk individuals harbouring these cardiac diseases in a timely fashion in the setting of preparticipation screening or medical consultation and provide appropriate advice regarding the participation in competitive sport activities and/or regular exercise programmes. Many asymptomatic (or mildly symptomatic) patients with cardiomyopathies aspire to participate in leisure-time and amateur sport activities to take advantage of the multiple benefits of a physically active lifestyle.

In 2005, The European Society of Cardiology (ESC) published recommendations for participation in competitive sport in athletes with cardiomyopathies and myo-pericarditis. One decade on, these recommendations are partly obsolete given the evolving knowledge of the diagnosis, management and treatment of cardiomyopathies and myo-pericarditis, The present document, therefore, aims to offer a comprehensive overview of the most updated recommendations for practicing cardiologists and sport physicians managing athletes with cardiomyopathies and myo-pericarditis and provides pragmatic advice for safe participation in competitive sport at professional and amateur level, as well as in a variety of recreational physical activities.

**Preamble**

The benefits of exercise on the cardiovascular system are well established and regular physical activity is an important component of minimizing the risk of several diseases. Participation in intensive exercise, however, may increase the risk of fatal arrhythmias in predisposed individuals. Inherited cardiomyopathies are among the leading causes of sudden cardiac death/cardiac arrest (SCD/CA) in young exercising individuals, including elite athletes. The link between cardiomyopathy and exercise-related SCD/CA is largely based on circumstantial evidence, due to the absence of systematic national registries. Nevertheless, based on the widespread impact of such tragedies on our society, there are several incentives to identify affected individuals on a timely basis through various screening processes, endorsed by the European Society of Cardiology (ESC) and the American Heart Association (AHA) (1,2,3).

The detection of a cardiomyopathy in an asymptomatic individual has important implications with respect to on-going participation in intensive exercise and competitive sport. In such circumstances, it is essential to strike a balance between protecting the athlete from the adverse effects of exercise (including adrenergic surges and hemodynamic loading) on abnormal myocardium and depriving the individual of the multiple benefits of exercise and a legitimate aspiration to excel in sport.

In 2005, the ESC published the recommendations for sport participation in athletes with cardiovascular diseases, which aimed to provide a practical guide for physicians (4). Over the past decade, there have been several developments pertaining to exercise and sport participation in individuals with the cardiomyopathies, such as 1) a better understanding of the clinical features of cardiomyopathies in athletes, 2) clarification of the natural history of the disease process in patients with arrhythmogenic cardiomyopathy, 3) novel methods of differentiating physiological adaptations to exercise and early phenotypic manifestations of cardiomyopathy, 4) the role of cardiovascular magnetic resonance (CMR) imaging in diagnosis and risk stratification in these patients, 5) the emergence of genotype-phenotype relationships in cardiomyopathies and , 6) the potential role of competition with an implantable cardioverter defibrillator (ICD).

Based on the aforementioned considerations, the sports cardiology nucleus was compelled to provide an update for physicians involved in the management of athletes with cardiomyopathies or myopericarditis. As previously, the document is intended to provide a practical guide to aid the physician in the management of the athletes with these disorders. In the absence of robust evidence, these guidelines largely reflect expert opinion and cannot be considered as legally binding. Therefore, they should not discourage individual physicians to practice outside the remit of this document, based on their scientific and professional experiences in sports cardiology. In contrast with the previous document, and in line with developments in good clinical practice, the present document encourages shared decision making with the athlete and respects the autonomy of the athlete after careful information about the potential risks of an adverse event.

**Shared Decision Making Process**

One of the shortcomings of managing athletes with heart disease is the scarcity of established risk stratification protocols in this cohort. Current risk stratification algorithms for patients with cardiomyopathy are derived from a sedentary population and are difficult to extrapolate to competitive athletes, who are subject to greater physical and metabolic stresses during intense exercise, which may culminate in fatal arrhythmias. Most deaths in athletes with cardiomyopathy affect individuals who do not have any of the conventional risk factors for SCD/CA Furthermore, deaths may occur several years after embarking an athletic career without prior symptoms.

The unpredictable nature of SCD/CA in sport has historically necessitated a cautious approach regarding advice for intense exercise and competitive sport in individuals with a cardiomyopathy (4). Such practice has inevitably affected several athletes who would never have experienced an adverse event during their entire sporting career and has been disputed as an intrusion into the personal freedom of the patient, rather than a precautionary measure aimed to reduce the unforeseeable risk associated with sport competition.

Based on the evolving knowledge in this field, we advocate adoption of an individualized approach that considers symptomatic status, established risk factors for SCD/CA, natural history of the disease, age of the athlete, duration of competition prior to the diagnosis and characteristics of the sport discipline, when advising participation or precautionary disqualification from competitive sport.

We are mindful that disqualification from competitive sport has extensive personal consequences for the athlete, even beyond the medical perspective, including loss or compromise of significant sums of financial remuneration and the athlete’s personal visibility. We therefore believe that it is crucial to involve the athlete in the decision-making process, which should include detailed information of the disease and open discussion about the potential risks associated with on-going competitive sport and high-intensity exercise programmes.

Athletes with full judgment and complete understanding who wish to participate in competitive sport despite contrary medical advice should not prejudice the examining physician. Furthermore, permission should be sought to inform attending coaches and team physicians to facilitate on-going clinical surveillance and to be prepared for managing SCA during training and competition.

Finally, we acknowledge that at present this process may be received differently in Europe, according to the cultural and societal rules and the medical competencies existing in each country (5). The weight of an athlete’s autonomy is also largely influenced by different legal systems in place and, therefore, the shared decision-making should be viewed and adapted in the context of the existing medical and legal rules.

Below, we provide a practical guide for the management of athletes with cardiomyopathy or myopericarditis. Based on novel data from cohorts of athletes with cardiac disease, the document includes brief updates in the diagnosis of cardiomyopathy in athletes and the risk stratification relative to exercise and sport participation. Finally, guidance for leisure sporting activities is also included to promote the cardiac and general benefits of physical activity in patients with cardiomyopathy.

**Diagnosis of Cardiomyopathy in Athletes**

The evaluation of athletes with suspected cardiomyopathy includes a detailed personal and family history, 12-lead ECG, echocardiogram, CMR imaging and additional investigations for risk stratification. The diagnosis of cardiomyopathy relies on cardiac imaging studies, although a large proportion of affected patients also demonstrate electrocardiographic abnormalities. The electrical, structural and functional changes encompassing the definitions of various cardiomyopathies are generally beyond the usual changes observed in response to athletic training, but a small proportion of athletes do exhibit electrical and/or structural changes that overlap with subtle forms of cardiomyopathy. Such diagnostic dilemmas more commonly affect black athletes (of West-African or Afro-Caribbean origin), and endurance athletes of all races. The differentiation between the physiological adaptation to exercise and cardiomyopathy is paramount, given the potential consequences of erroneous interpretation. The presence of cardiac symptoms and family history of cardiomyopathy are important red flags for pathology. Specific enquiry regarding epilepsy, drowning or unexplained fatal car accidents is relevant because arrhythmic events may present in such fashion. The current document outlines the pertinent electrical, structural and functional features, which facilitate the differentiation between physiological cardiac adaptation and cardiomyopathy in athletes (6).

**Hypertrophic Cardiomyopathy**

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease caused predominantly by mutations within genes encoding sarcomeric contractile proteins and is characterized by a hypertrophied left ventricle (LV) in the absence of cardiac or systemic disease capable of inducing the same magnitude of LV hypertrophy (7,8). The condition is of special interest because it is one of the most common causes of exercise-related SCD/CA in athletes (9-11). The vast majority of the young/adult athletes with HCM are asymptomatic and are identified following the investigation of an abnormal ECG. However, angina, syncope or palpitation are recognised presenting features of the disease.

*Electrocardiography:* The 12-lead ECG is abnormal in over 95% of adult athletes with HCM (12-14). Large QRS voltages are common in all individuals with HCM irrespective of athletic status. Concomitant inferior and lateral T-wave inversion, ST-segment depression and pathological Q waves are the most common abnormalities. Of note, lateral T-wave inversion has a 14% diagnostic yield for HCM, but is also detectable in 4% of normal black athletes (15). Electrical anomalies may precede overt structural disease by several years (16). A minority (5-10%) of young individuals with HCM may have a normal ECG, or increased R/S wave voltage in isolation (14).,

*Echocardiography:* The diagnosis of HCM is based on the presence of unexplained LV hypertrophy with maximum end-diastolic wall thickness >15 mm in any segment on 2D echocardiography or CMR imaging (7,8). The diagnosis of HCM may be considered in individuals with a LV wall thickness of 13-15 mm in the context of another family member fulfilling conventional diagnostic criteria for HCM, or positive genetic testing, or the aforementioned repolarization anomalies (6-8). Whereas the maximal LV wall thickness rarely exceeds 12-13 mm in healthy white athletes (2%), this scenario is relatively common (13-18%) in male black athletes, who may reveal a LV wall thickness measurement of up to 16 mm (6,14,17-20). The morphologic overlap between physiological LV hypertrophy and HCM is less common in adolescent athletes, and observed in <1% of white athletes, but up to 7%, in African athletes (21,22). Notably, LV wall thickness does not exceed 11 mm in white female athletes and 13 mm in black female athletes (18,23).

As with sedentary HCM individuals, most athletes with HCM show an asymmetric pattern of LV hypertrophy (6-8) and in one series, approximately one-third of athletes with HCM had the apical variant (14). In contrast, athletes with physiological LV hypertrophy show a more homogeneous and symmetric distribution of wall thickness, with only mild differences between contiguous segments and a symmetric pattern of LV hypertrophy (17).

 LV hypertrophy usually becomes evident during adolescence or early adulthood (7,8), but may not be manifest phenotypically until the 4th or 5th decades of life. LV end-diastolic cavity size in individuals with HCM is normal or reduced, whereas athletes with physiological LV hypertrophy usually reveal an enlarged cavity (i.e., LV end-diastolic diameter >54 mm) (19). A subset of HCM athletes with the apical variant (about 15%) may demonstrate an enlarged LV cavity size (14). Other subtle structural anomalies supporting the diagnosis of HCM include elongation of mitral valve leaflets, anomalous insertion of papillary muscles, or myocardial crypts and recesses (7,8).Although diastolic function is usually abnormal in sedentary patients with HCM patients, most athletes with HCM reveal normal indices of diastolic transmitral filling (14,19) and reliance on abnormal transmitral Doppler filling pattern to exclude HCM has poor sensitivity in athletes. Abnormalities of the relaxation pattern of Tissue Doppler Imaging (TDI) may, however, be present in the early stage of the disease (6). According to a study of 1510 athletes and 58 young asymptomatic individuals with HCM (50% of whom had a LV wall thickness ≤ 15 mm), septal E’ < 12 cm/sec and lateral E’ < 12 cm/sec on TDI were the best diastolic markers for HCM (24). LV systolic function is usually within the range of normality in both athletes and HCM patients. Only subtle differences in myocardial contraction may be detected by the LV strain assessment (6).

*Cardiac magnetic resonance* (CMR): Cardiovascular magnetic resonance imaging is recommended in all athletes with equivocal findings, such as LV wall thickness of 13-16 mm, major electrical abnormalities (deep T-wave inversion in the inferior and/or lateral leads), or symptoms suggestive of cardiac disease in the context of a family history of HCM. CMR has unrivalled value in excluding localized hypertrophy, in segments that cannot be visualized adequately with echocardiography, such as the LV apex or the antero-lateral segments. The presence of late gadolinium enhancement (LGE) with non-ischemic pattern in the hypertrophied segments is suggestive of myocardial fibrosis, and consistent with the diagnosis of HCM (25,26).

*Exercise and Cardio-pulmonary test (CPET) and 24-48 hour Holter monitoring:* The presence of symptoms, non-sustained ventricular tachycardia, or ST segment depression /T wave inversion during exercise, or flat blood pressure response (< 20 mm Hg rise in systolic pressure from baseline to peak exercise) and a low peak oxygen consumption (<84% predicted) are in favour of pathological LV hypertrophy (27). Normalization of basal T-wave inversion or ST-depression during exercise does not exclude HCM.

Similarly, the occurrence of non-sustained ventricular tachycardia or any complex ventricular arrhythmias in an athletic individual with a LV wall thickness >12 mm ≤16 mm during 24-h (or 48-h) ECG monitoring also favours the diagnosis of HCM.

*Genetic testing:* Genetic testing in athletes with an equivocal diagnosis of HCM should only be performed after detailed clinical and family assessment by an experienced cardiologist, as the absence of a sarcomere mutation does not exclude familial HCM and variants of uncertain significance can be difficult to interpret (16). For this reason, genetic testing is currently recommended only in patients clearly fulfilling the diagnostic criteria for HCM, to enable cascade genetic screening of their relatives (28)

*Detraining:* Finally, when the differential diagnosis cannot be resolved with conventional tests, useful information may be gained from detraining. Serial echocardiographic studies demonstrating regression of LV hypertrophy after a 3-month period of complete deconditioning in an athlete without family history of HCM are consistent with diagnosis of physiological LV hypertrophy (29).

**Risk stratification:**

Risk stratification in athletes with HCM is challenging, due to lack of prospective studies reporting the outcome of the disease in patients engaging in regular, intensive exercise. The current ESC (7) and AHA (8) algorithms to assess the risk of SCD in the general HCM population cannot be extrapolated to individuals regularly exposed to the hemodynamic and metabolic stresses of an athletic lifestyle.

Circumstantial evidence has suggested that intensive exercise and sport participation itself may play a role in triggering SCD/CA. Among youngathletes in US, HCM is the most common cause of exercise related SCD/CA (9). Participation in high-intensity competitive sports itself has been considered as an independent risk factor for SCD/CA, even in the absence of the conventional risk markers, due to accompanying alterations in hydration, electrolyte and acid base status and surges in catecholamine levels (30).The incidence of SCD is significantly higher in highly-dynamic sport, such as basketball, football, swimming, particularly in athletes of Division I compared to Division II and III, suggesting that intensity of training and level of achievement might have a causative role (31)(32)The age of an athlete may also have an impact on risk. The mean age of athlete in the largest series of SCD from the US was 17.1 years old (9). In a recent report of outcomes in over 11,000 screened soccer players aged 16-17 years old who were followed up for just over 10 years, 2 of the 8 cardiac deaths occurred in individuals diagnosed with HCM who chose to continue playing despite medical advice (32).

On the other hand, retrospective observations indicate that SCD/A is relatively rare in HCM even among affected individuals who exercise regularly individuals. Lampert et al. reported that individuals with HCM who were implanted with an ICD had similar rates of appropriate or inappropriate shocks during exercise or at rest (34). A case series of HCM athletes, previously reported by Maron et al. (35) already introduced the concept that within the large spectrum of the disease, there are individuals who can engage in intense athletic training and competitions for many years, without incurring symptoms or clinical worsening or dying suddenly. Recently, Pelliccia et al. reported that in a small cohort of 35 athletes with HCM , who were followed up for a 9-year period, there were no differences in the incidence of symptoms or major events between athletes who had become sedentary (n=20) after diagnosis and athletes who continued to engage in competitive sport (n=15). In this cohort there was one cardiac arrest during the surveillance period, which was unrelated to exercise (36).

Overall, the current literature indicates that not all individuals with HCM are vulnerable to fatal arrhythmias despite engaging in exercise programmes. In this regard, systematic restriction from competitive sport in all affected individuals is probably unjustified and a more liberal approach to sport participation may be reasonable after considering the age of the athlete, duration in competitive sport prior to diagnosis and the presence of conventional risk factors for SCD. It is indisputable, however, that absence of all major risk factors does not convey immunity to SCD, and even patients with low-risk may die suddenly (37) Therefore, when advising an individual with HCM regarding participation to intensive exercise programmes and competitive sport this consideration should be an integral part of discussion during the shared decision making process.

**Recommendations:**

Participation in intensive exercise programmes and competitive sport should be considered on an individual basis, after full evaluation of the disease characteristics and risk determinants. Specifically, conditions that reasonably represent absolute contraindications for sport participation include: 1) symptoms, particularly unheralded syncope; 2) previous history of aborted SCD/CA; 3) exercise induced ventricular tachycardia; 4) high ESC 5-year risk score (7) and 5) documentation of a significant increase in LV outflow gradient (> 50 mm Hg) and 6) abnormal blood pressure response to exercise.

Following comprehensive explanation of the disease characteristics, risk factors and potential outcomes and assuring that a reasonable understanding and agreement has been reached between the athlete and the physician, it seems reasonable that adult athletes with mild clinical expressions of HCM and low risk profile may be allowed to participate in all competitive sports, with exception of those where syncope may have be associated with harm or death (see Figure 1). Such athletes should be reviewed annually to assess symptoms and changes in risk profile.

This recommendation should be viewed in the context of the cultural and customary medical care in place and should not override the existing medical and legal boundaries existing in the different countries.

 (Class IIb; Level of Evidence C).

**Genotype-positive, phenotype-negative HCM athletes**

Advances in the molecular genetics of HCM coupled with improvement in methods for gene sequencing has resulted in an increasing number of asymptomatic relatives of HCM patients being detected as gene-carriers in the absence of morphological or clinical features of HCM. Several reports have suggested that such individuals (G+P-) may exhibit a number of subtle abnormalities, such as high concentration of serum biomarkers of collagen synthesis, expanded extracellular volume at T1 mapping on CMR, LV wall thickness at upper normal values and subtle impairment of myocardial relaxation (38-40).

Over the past few years, a limited number of studies have suggested that G+P- individuals have a benign clinical course, with absence of symptoms or adverse events and a small number develop the phenotype in the third decade, suggesting incomplete penetrance during most of a competitive athlete’s career (41-43).

Although the number of individuals studied in these reports, and their follow-up was limited, it is important to emphasize that there were no clinical events in mutation carriers before the development of an overt HCM phenotype (i.e. LV hypertrophy). In conclusion, available evidence from relatively small studies suggests that gene carriers for HCM do not incur risk until the phenotypic spectrum of the disease is developed and, therefore, the G+P- status should not equate to having the disease.

**Recommendations.**

G+P- individuals should be assessed to exclude the broader phenotypic and clinical features of HCM (with ECG, CMR, exercise test and 24-hour ECG). In the absence of phenotypic features of HCM these athletes may be allowed to engage in all competitive sports. (Class IIa; Level of Evidence C).

There is limited data in individuals with positive genotype and an abnormal ECG in isolation, therefore until further data is available the panel recommends that such individuals are managed similarly to those without LV hypertrophy (44).

 (Class III; Level of Evidence C)

Adolescent athletes G+/P-, should undergo periodical surveillance (at least, yearly), to monitor the potential progression to the overt HCM phenotype. A more liberal attitude is justified in adult (> 25 years old) athletes, with recommended follow-up every two-years.

**Dilated Cardiomyopathy**

Dilated cardiomyopathy (DCM) is a myocardial disease characterized by a dilated and hypokinetic LV or both ventricles (with or without associated right ventricular dysfunction) (45). DCM may be genetic in origin, or secondary to infection or inflammation, toxic agents, ischemia or idiopathic. Although infrequent, DCM is a recognized cause of SCD in athletes.

 Athletes with an enlarged LV cavity with mildly reduced systolic function and/or associated ventricular arrhythmias fall into a grey zone between physiological LV enlargement and DCM.

*12-lead ECG:* The ECG may be normal or show similar changes to those of athletic training, such as voltages for atrial enlargement, axis deviation or, large QRS voltages in the lateral leads. Recognized electrical manifestations of DCM include T-wave inversion, intraventricular conduction defect, or left bundle branch block (LBBB). Of note, some ECG alterations, such as 1st degree atrio-ventricular (AV) block or pathological Q waves in the inferior and/or-lateral leads may be expressions of specific genotypes (i.e., Lamin A/C or dystrophin) mutations. Occurrence of ventricular arrhythmias, particularly during exercise, may be common (46).

*Echocardiography*:In DCM, the LV cavity is usually enlarged and LV shape becomes more spherical with time, when the mitral annulus enlarges with distortion of leaflets and resultant valvular regurgitation. Most importantly, LV systolic function is reduced and the ejection fraction is usually below 50%. Regional wall motion abnormalities are occasionally present (47).

It is recognised that male athletes engaged in mixed and endurance sport frequently demonstrate an enlarged LV cavity size. Approximately 15% of elite male athletes show a LV end-diastolic diameter >60 mm (48). LV cavity enlargement in athletes should be interpreted in the context of the sporting discipline and body size (it is advised to relate LV cavity to BSA) and is usually associated with increased wall thickness (6,48,49).

The presence of concomitant RV remodeling, with normal RV function is consistent with a physiologic LV remodeling (6).

Occasionally, athletes with an enlarged LV cavity may demonstrate a mildly reduced LV ejection fraction (i.e., >45%, <55%) and bradycardia (50). In this scenario, the differentiation between physiological LV remodeling and DCM may be challenging. In such instances, regional wall motion abnormalities and abnormal diastolic function may support DCM. Exercise echocardiography (or CMR) are both effective methods for assessing myocardial reserve and an increase in LV ejection fraction of >10-15%, during exercise, supports the diagnosis of physiological LV dilatation (51,52).

*Cardiac Magnetic Resonance:* CMR is the gold standard for the assessment of biventricular dimensions and function in equivocal cases. In DCM, LGE identifies focal replacement fibrosis and it is detectable in approximately one-third of patients with a distinctive mid-wall distribution. The presence of mid-wall LGE and its extent has emerged as an important tool in risk stratification of DCM (53,54). Exercise CMR is useful for assessing myocardial reserve.

*CPET and 24-h Holter monitoring:* In DCM patients, exercise performance may be only mildly impaired in the early stages of the disease, and may not be sensitive for differentiating physiological from pathological LV remodeling. However, the presence of a low peak oxygen consumption in an athlete with an enlarged LV and borderline/low LV ejection fraction supports DCM.

Arrhythmias are reported in approximately 30% of DCM patients and may be present even in the presence of only mildly dilated LV cavity (55,56). In this regard, 24-hour ECG monitoring (including a training session) is of particular importance in the risk stratification of DCM patients.

**Risk stratification:**

The clinical course of DCM is variable and cardiac events (including SCD/CA) are related to LV function and the presence of atrial and ventricular tachyarrhythmias. The risk of adverse consequences in patients with DCM participating in regular exercise programmes is largely unknown, due to the lack of long-term observational studies. However, scientific evidence from rehabilitation studies in heart failure supports the concept that high-intensive exercise programmes are feasible and beneficial in patients with idiopathic DCM, and are not associated with an increased risk of SCD/CA (57, 58).

**Recommendations**:

Participation in intensive exercise programmes and competitive sport should be considered on an individual basis, after evaluation of the disease characteristics and risk determinants. Advising an athlete with DCM regarding participation in competitive sport requires a comprehensive and clear explanation, and assurance of understanding of the associated risk on behalf of the athlete,.

1. The presence of LV cavity dilatation with preserved LV function, in the absence of a family history of DCM, abnormal ECG patterns and atrial/ventricular tachyarrhythmias should not be considered to represent expression of physiological cardiac remodeling rather than DCM. Therefore, no restriction to competitive sports is applicable to this cohort of athletes. (Class IIa, Level of evidence B)

2. Athletes with an unequivocal diagnosis of DCM, but mildly reduced LV systolic function (EF ≥40%) may selectively engage in all competitive sport with the exception of those where syncope may be associated with serious harm or death (Figure 1) if they are asymptomatic, without prior history of unexplained syncope and without frequent/complex ventricular tachyarrhythmias on ambulatory ECG monitoring and exercise testing. Exceptions include patients with a family history of SCD/CA and/or those previously identified with mutations during cascade screening for familial DCM, which are associated with an increased risk of life-threatening arrhythmias (such as Lamin A/C or Filamin C mutation), irrespective of the severity of LV dysfunction and dilatation. These patients should be advised not to engage in competitive sports. (Class IIb; Level of Evidence C).

3. Athletes with a diagnosis of DCM who are symptomatic, or have a LV ejection fraction <40%, or extensive LGE (i.e., >20%) on CMR and/or frequent/complex ventricular tachyarrhythmias on ambulatory ECG monitoring and exercise testing, or prior history of unexplained syncope should be advised not to engage in competitive sports. (Class III; Level of Evidence C) These patients should be advised to limit their exercise programmes to leisure-time activities and undergo regular clinical surveillance, consistent with current recommendations for the management of DCM.

**Genotype-positive, phenotype-negative DCM athletes**

Currently, there are over 50 genes implicated in DCM, which encode sarcomeric, cyctoskeletal, nuclear envelope and sarcolemmal proteins, ion channels and intercellular junctions (59).

The impact of regular exercise training on the natural history of G+/P- individuals is not yet fully understood, although individuals with an isolated pathogenic variant , in the absence of overt phenotypic features of DCM, should be not considered to have the disease.

**Recommendations.**

The G+P- athletes should be assessed to exclude the phenotypic and clinical features of DCM (including CMR, exercise test and 24-hour ECG). In the absence of evidence for DCM, these individuals may be allowed to engage in all competitive sports, with the recommendation to undergo a periodical evaluation, at least annually, in order to early detect the phenotypic expression of the disease. (Class IIa; Level of Evidence C).

**Left Ventricular Non Compaction Cardiomyopathy**

Left ventricular non-compaction (LVNC) is a relatively novel cardiomyopathy characterized by prominent trabeculations within the LV myocardium, separated by deep recesses, usually associated with LV dysfunction. (60) The disease has a genetic basis in some instances and a variety of inheritance patterns have been reported. Clinical presentation of LVNC includes varying degrees of systolic heart failure, ventricular tachyarrhythmias and/or systemic thromboembolism (60). In athletes, however, a suspicion of LVNC usually emerges in the absence of symptoms, based on the identification of a prominent trabecular pattern by cardiac imaging (6).

*12-lead ECG:* Common ECG abnormalities in LVNC include T-wave inversion, ST-segment depression or ventricular conduction delay, mostly LBBB (61).

*Echocardiography/CMR:* The morphologic diagnosis of LVNC relies on the presence of a 2-layered structure of the myocardial LV wall on imaging testing. Current diagnostic criteria are based on the demonstration of a high ratio of non-compacted to compacted layer of the LV myocardium, either at echocardiography (i.e., ratio > 2) or at CMR (> 2.3), although the validation of these criteria has been questioned (6, 62,63). Additional supportive features include LV systolic dysfunction, with reduced (< 50%) ejection fraction, but also a very thin compacted epicardial layer (i.e., <8 mm in systole on echocardiography) (61) and abnormal myocardial relaxation (e’ <9 cm/s at TDI (64).

Athletes frequently show increased trabeculations in the LV cavity (i.e., so-called hypertrabeculation pattern), and up to 8% may fulfill the morphological criteria for LVNC (65). It has been postulated that an increased cardiac preload may simply unmask pre-existing trabeculations and make them more prominent. This hypothesis is supported by a longitudinal study, using the pregnancy model, which showed that almost 25% of primigravida women developed prominent trabeculation and 8% fulfilled criteria consistent with LVNC as pregnancy progressed to the third trimester (66).

Only a small proportion (0.9%) of athletes with hypertrabeculation exhibit other clinical abnormalities supportive for diagnosis of a cardiomyopathy; these athletes need to be thoroughly investigated (65). Specifically, athletes with LV hypertrabeculation and an abnormal ECG and/or mildly reduced LV function, or positive family history should undergo a complete evaluation including CMR and exercise echocardiography to assess the LV response to effort, and ECG Holter monitoring to ascertain the presence of arrhythmias, all findings that will support the diagnosis of LVNC (6, 65,67-71).

**Risk stratification**

The clinical outcome of LVNC is variable, even within families, and governed by the magnitude of LV dysfunction and prevalence of atrial and ventricular arrhythmias or thromboembolic events. Adverse consequences are largely associated with LV systolic dysfunction or major ventricular tachyarrhythmias. It is noteworthy that no major cardiac events have been reported in the absence of LV dysfunction, regardless the severity of hypertrabeculation (65,67,68, 70,71)*.*

R**ecommendations**.

As specified above, advising an individual with LVNC regarding participation to competitive sport requires a comprehensive and clear explanation, and assurance of understanding of the associated risks on behalf of the candidate.

1. Athletes with incidental discovery of LV hypertrabeculation should not be diagnosed as LVNC in the absence of symptoms, positive family history, abnormal ECG patterns and, most importantly, impaired LV function. In such cases, no restriction for all competitive sports apply (Class IIA, Level of evidence B)

2. Athletes with unequivocal/reasonable diagnosis of LVNC but near-normal LV systolic function may participate in all competitive sports with the exception of those where syncope may cause serious harm or death (Figure 1), if they are asymptomatic, without frequent and/or complex ventricular arrhythmias, or non-sustained VT on ambulatory monitoring and exercise ECG testing, and no prior history of unexplained syncope (Class IIb; Level of Evidence C).

3. Athletes with an unequivocal diagnosis of LVNC and impaired LV systolic function or frequent and/or complex ventricular arrhythmias, or non-sustained VT on ambulatory monitoring or exercise testing should be advised to abstain from participation in competitive sports (Class III; Level of Evidence C). These patients should be advised to limit their exercise programmes to leisure-time physical activities and remain under regular clinical surveillance.

**Arrhythmogenic (Right Ventricular) Cardiomyopathy**

Arrhythmogenic right ventricular cardiomyopathy (ARVC), or simply arrhythmogenic cardiomyopathy (AC) is an inherited myocardial disease caused predominantly by mutations in genes encoding desmosomal proteins. The disease is characterized histologically by fibro-fatty replacement of the right ventricle and/or LV myocardium, and clinically by life-threatening ventricular tachyarrhythmias (72). Sudden death usually occurs in young AC individuals and is often triggered by exercise. AC represents a common cause of SCD in prospective studies of young athletes in Italy (73) and in an unselected population of young adults from Australia (74).

The diagnosis of AC is based on the criteria proposed by an expert consensus panel that recognize electrophysiological, anatomical and clinical features of the disease (75).

*12-lead ECG:* The ECG is of particular value in raising suspicion for AC and is abnormal in the majority (>60%) of individuals (76). The most common abnormalities in the right-dominant variant include inverted T-waves in the right precordial leads (V1-V3), prolonged QRS duration >110 msec with right bundle branch block (RBBB) pattern and a delayed upstroke (>55 msec) of the S wave in V1-V2. Rare is the presence of an epsilon wave in V1 or V2. In the left-dominant variant low voltages of R/S wave in the limb leads are increasingly recognized, as well as the presence of diffuse T-wave inversion in the antero-lateral and inferior leads (72,76). Not rarely, isolated premature ventricular beats (PVBs) are present, typically with LBBB pattern and vertical axis (in the right-variant), or RBBB and superior axis (in the left-variant). Electrical changes may precede morphological abnormalities by several years (72).

*Echocardiography and CMR*: Echocardiography and CMR may show an enlarged right ventricular (RV) cavity in the right-dominant variant, with morphologic abnormalities (i.e., thinning, bulging and aneurysms of the RV wall), associated with wall motion abnormalities, which are evident only in advanced stage of the disease (6). In the right-variant, the outflow tract is commonly more enlarged respect to the inflow tract (77). In the early stage of the disease, however, morphologic RV changes may be only mild or not so evident.

Although 2D echocardiography provides a readily available imaging tool, it has important limitations for visualizing the complex geometry of the RV. Therefore, modern imaging relies more on CMR, which has superior diagnostic value in identifying segmental morphologic RV abnormalities, including regional wall motion anomalies (6,78).

In the left-dominant AC, the morphologic abnormalities of the LV may be mild or even undetectable at echocardiography, and CMR is the only imaging test to identify altered signal intensity, consistent with fibro-fatty replacement in the sub-epicardial region or mid-wall of the LV (72,78).

It is well known that endurance athletes develop an enlarged RV cavity in association with enlarged LV, both with preserved shape, as consequence of the physiologic adaptation of both ventricles to chronic exercise training (79,80). The physiological RV remodeling in athletes is characterized by a proportionate increase in the inflow and the outflow tract and the absence of segmental morphologic thinning or wall motion abnormalities (6,79,80). The RV dimensions by themselves may be insufficient to distinguish physiologic from pathologic RV remodeling and need to be associated with wall motion abnormalities to suggest AC (75). Finally, care should be taken to avoid misinterpretation of certain CMR findings in athletes as pathological (such as RV apex dilatation, or localized apical bulging of the RV wall at the level of the moderator band) (78).

Similar to DCM, exercise imaging (by echocardiography or CMR) may be useful for discriminating between physiologic RV enlargement with preserved systolic function in healthy athletes from pathologic RV myocardial remodeling in AC (52).

*CPET and 24-h Holter monitoring:* In young AC patients, exercise performance may be preserved. However, ventricular arrhythmias (PVBs and/or VT with LBBB morphology in the right-dominant, or RBBB in the left-dominant), are usually present at an early stage of the disease, and are usually triggered by exercise.

*Genetic testing*: In patients with ARVC, the most commonly affected genes encode desmosomal proteins (72). The overall rate of successful genotyping among patients meeting the diagnostic criteria for ARVC is not more than 50% (81). Moreover, the interpretation of an apparently positive genetic test is made challenging by the difficulty in differentiating pathogenic variants for ARVC, especially missense mutations, from non-pathogenetic variants and polymorphisms present in a minority of normal population (82).

Clinically, genotyping is indicated to identify a pathogenic variant mutation in a proband who already fulfills the phenotypic diagnostic criteria in order to facilitate cascade screening of first degree relatives. Genotyping should not be used to confirm the diagnosis in an isolated patient with a borderline or questionable phenotype. .

**Risk stratification**:

In predisposed individuals, with abnormal cell-to-cell binding of the myocytes, the dilation of the RV associated with regular exercise training may lead to myocardial damage and subsequent fibro-fatty replacement, thereby triggering the morphological features of the disease. Ventricular tachyarrhythmias and sudden death in AC commonly occur in association with exertion and AC accounts for a substantial proportion of deaths in young athletes (72,83). .

Prior aborted SCD, unheralded syncope, ventricular tachycardia and impaired right and/or left ventricular function are established risk factors for arrhythmogenic cardiac arrest in AC. Exercise also appears to be an independent risk factor for expediting the disease phenotype and promoting fatal arrhythmias (72,83,84).

 In an experimental murine model of cardiac desmoplakin mutations, exercise training has been shown to increase the penetrance and the arrhythmic presentation of he disease (85,86). Similar results have been confirmed in AC genetically positive human patients. Specifically, James et al. investigated the penetrance of AC in 87 desmosomal mutation carriers, and found that endurance exercise training was associated with higher penetrance of the disease, earlier onset of symptoms, and increased risk of ventricular tachyarrhythmias and heart failure (87)*.*  Saberniak et al. investigated myocardial function in AC patients, and found reduced RV function in athletes AC when compared with non-athletes AC (88). Recently, the results from the North American multidisciplinary study of ARVC (89) found that patients engaged in competitive sport were incurring a larger incidence of ventricular tachyarrhythmias/death and earlier presentation of symptoms, compared with patients who participated in only recreational physical activity and those who were sedentary. Among patients engaged in competitive sports, early age of sport initiation was associated with premature presentation of symptoms and adverse clinical profile. Reducing exercise intensity was associated with a substantial decrease in the risk of ventricular tachyarrhythmias or death, to the same level as inactive patients (89). In summary, the overall scientific evidence supports the concept that participation in competitive sport is associated with earlier onset of symptoms and greater risk of ventricular arrhythmias and major events in AC patients.

These considerations are clinically relevant and support a restrictive advice regarding the participation in intensive exercise programmes and competitive sports in affected AC patients. Conversely, recreational exercise program conveys a reduced risk, such as that of patients physically inactive.

R**ecommendations**

Advising an athlete with AC regarding participation to exercise programmes or sport requires a comprehensive and clear explanation, and assurance of an understanding of the whole spectrum of exercise-related risks on behalf of the candidate,. Then, this panel recommends:

1. Athletes with unequivocal or probable diagnosis of AC should not participate in competitive sports.

(Class IIa; Level of Evidence C).

These patients should be advised to limit their exercise programs to leisure-time activities, and remain under clinical surveillance.

Of note, life-long endurance athletes  presenting with clinical features indistinguishable from AC, but without desmosomal mutations, are often referred to as “gene-elusive AC” or “exercise-induced right ventricular cardiomyopathy” (90-93). The work-up and recommendations in these athletes are identical as in inherited AC, as outlined above.

**Genotype-positive, Phenotype-negative AC athletes.**

 A number of studies involving carriers of pathogenic desmosomal mutations, predominantly plakophilin-2 (PKP2) have shown that asymptomatic G+P- family members who exercise regularly are more likely to fulfill the criteria for the diagnosis, and develop potentially fatal arrhythmias and heart failure compared to sedentary G+P- counterparts (87,88). Based on these reports, exercise recommendations in athletes who are G+P- with pathogenic desmosomal variants, are identical to those assigned in athletes with overt AC.

**Recommendations.**

Athletes who are genetic carriers of pathogenic AC-associated desmosomal mutations (even in the absence of phenotypic expression of the disease) should not participate in competitive sports. These athletes should be advised to limit their exercise programs to leisure-time activities and remain under clinical surveillance. (Class IIa; Level of Evidence C).

**Athletes with Isolated ECG Abnormalities.**

Asymptomatic athleteswithisolated ECG abnormalities suggestive of cardiac pathology (such as ST-segment depression, T-wave inversion, and pathological Q waves) in the absence of positive family history of SCD/CA or structural features of a cardiomyopathy on imaging tests deserve special attention*.* Several observations in athletes suggest that these ECG abnormalities, particularly T-wave inversion in inferior and lateral leads, are harbingers for the development of overt cardiomyopathies over the medium to long-term follow-up (15,16,94). These athletes should be comprehensively evaluated with CMR, exercise stress test and 24-h Holter ECG monitoring and clinical evaluation of first-degree relatives if possible, to exclude the possibility of cardiomyopathy (44,95).

**Recommendations.**

Athletes with a markedly abnormal ECG who do not reveal any other features of cardiomyopathy should not be considered as affected by cardiomyopathy and may continue to participate in all competitive sport.

(Class IIa, Level of Evidence C)

However, given the potential for developing a patent cardiomyopathy later on life, it is important that these individuals are assessed periodically (annually during adolescence and young adulthood) and educated with respect to the potential development of cardiac symptoms.

**Athletes with cardiomyopathy and implanted cardioverter defibrillator (ICD)**

The efficacy of the implantable cardioverter defibrillator (ICD) in aborting SCD/CA in high-risk individuals with cardiomyopathy has led to several young active being implanted for primary and secondary prevention. A significant proportion of such individuals aspire to continue engaging in team and individual sport at competitive and recreational level and the issue of safe sport participation in ICD recipients has become highly relevant.

The risks associated with sports participation in athletes with ICDs was assessed in the multinational, prospective ICD Sports Safety Registry (34,96) which enrolled 440 participants, including a substantial proportion of patients with HCM (n=75, 17%), and ARVC (n=55, 13%). After a mean follow-up period of 4 years, there were no arrhythmic deaths, externally resuscitated tachyarrhythmias during sports participation, or injury resulting from arrhythmia-related syncope or shock during sports. These results suggest that exercise and sport participation are feasible and safe in cardiomyopathy patients with ICD. Medium -term data of this registry suggests that among clinical and demographic variables associated with receiving appropriate shocks during competition/practice, the most relevant was the presence of ARVC (96).

A measure of caution regarding sport participation in patients with cardiomyopathies is, however, justified considering that more participants received shocks during competition/practice or physical activity than at rest (20% versus 10%; p<0.001) and specifically, the proportion of appropriate shocks was greater during competition or other physical activity than during rest (11% versus 6%; P=0.005). Indeed, of 51 subjects who received shocks during sports, 20 decided to quit their sport practice. Finally, there were 31 definite and 13 possible lead malfunctions (10% of the overall cohort) (96).

In conclusion, athletes with cardiomyopathies and ICDs may participate in competitive sports without adverse events in the medium term; however, 1 in 5 will receive both appropriate and inappropriate shocks (96).

Evaluation of individuals with cardiomyopathy and ICD who are willing to participate in competitive sport should be preferentially performed in experienced centers.

R**ecommendations**

Advising participation in exercise programmes and sport in patients with ICD necessitates a comprehensive and clear explanation, and assurance of an understanding on of the whole spectrum of exercise-related risks behalf of the candidate,. At this regard, we recommend:

1. The indications for an ICD in competitive athletes should not differ from the general population with a diagnosis of cardiomyopathy. Specifically, the desire of the athlete with cardiomyopathy to compete should not constitute a primary (or unique) indication for ICD implantation. (Class II; Level of Evidence C).

2. Recommendation for sports participations in an individual with an ICD should be based on the fact that the arrhythmogenic substrate of the cardiomyopathy remains unaltered and the ICD does not prevent insurgence of a malignant arrhythmia, especially during intensive exercise , although it will prevent SCD/CA. (Class II; Level of Evidence C).

3. Participation in competitive sports may be considered in the individual patient with cardiomyopathy and ICD, after careful consideration of the type of underlying cardiomyopathy (for instance, AC represents reason for contraindication), and personal attitude. The decision to participate in competitive sport should be made after full disclosure of the risks of sport participation with ICD, including the likelihood of appropriate/inappropriate shocks, leads failure and the device-related trauma (Class IIb; Level of Evidence C).

Given the concerns about lead problems in the longer term, there is currently a large interest in the applicability of subcutaneous-ICD devices in athletic patients. Initial experience with subcutaneous-ICD shows a high efficacy, although the current lack of data limit our understanding on long-term benefits and pitfalls (97,98)

With regard to type of sport, selected patients with cardiomyopathy and ICD may participate in all sport, with exception of sports with bodily contact, such as rugby, American football and martial arts in order to avoid damage to the generator box and the cardiac leads (see Figure 1). For other sports with a smaller collision risk, such as soccer, basketball and hockey, some have advocated padding of the ICD implantation site, although effectiveness of these protection systems has not been proven (98).

Patients with cardiomyopathy and ICD should avoid sports where transient syncope from an arrhythmia or the jolt of a shock may cause serious injury or death, such as mountain climbing, surfing, motor racing or deep sea diving (Figure 1) (98,99).

Strong magnetic fields could temporarily inhibit tachyarrhythmia therapy or lead to inappropriate interventions. Patients should be informed about the possibility of encountering any sports-related exposure to electromagnetic fields.

**Prescription for leisure-time physical activity in patients with cardiomyopathy.**

The clinician is frequently confronted with the request of designing leisure-time exercise programmes for young individuals with cardiomyopathies, who aspire to maintain a physically active lifestyle. The precise risk of habitual non-competitive sport activities in young and adult patients with cardiomyopathy is poorly defined. It has been argued that a certain degree of risk associated with participation in amateur and leisure-time sport activities will likely persist.However, given the plethora of benefits of moderate exercise on the cardiovascular system and longevity of life, it would seem appropriate to prescribe exercise programmes in all individuals with cardiomyopathy (99-101).

In recent years, there has been accumulating scientific evidence to support the benefits of regular exercise programmes in patients with cardiomyopathy. A recent randomized clinical trial demonstrated that patients with HCM may safely engage in moderate-intensity, regular exercise programmes (102). Just after 16 weeks of an active lifestyle, a mild (+6%), statistically significant increase in VO2 max and exercise capacity was observed. Of relevance, there were no episodes of sustained ventricular arrhythmia, cardiac arrest, or appropriate defibrillator shocks even in patients with a moderate or high-risk profile (102). Klempfner et al. reported similar results in symptomatic HCM patients enrolled in a supervised cardiac exercise program (103). After a short-term period (average, 40 hours exercise) the vast majority of patients (80%) reported subjective improvement in their clinical condition and the NYHA class improved from baseline by >1 grade. Functional capacity, assessed by the change in maximally attained METs, improved by 46% and during the 12 month follow up period, none of the patients experienced clinical deterioration, significant adverse events or ICD discharges (103).

It is reasonable that the actual risk associated with mild to moderate exercise programmes is less than previously anticipated and, therefore, the majority of patients with HCM should not be deprived of the many cardiovascular, metabolic and psychological benefits afforded by regular exercise. Regular exercise improves functional capacity and may reduce the impact of excessive body weight on symptom progression in HCM patients, in whom obesity promotes worsening of the disease (104).

Although it is well recognised that intensive exercise programmes aggravate the clinical course in patients with AC, there also is evidence that recreational and low-intensity exercise may not have an adverse impact on the natural history of the disease. In the North American multidisciplinary study of ARVC (89) there were no differences in RV volumes between sedentary patients and those participating in recreational sports and there were no differences in age at clinical presentation or incidence of ventricular tachyarrhythmias or SCD/CA between inactive patients and patients who participated in mild recreational physical activities. Therefore, recreational exercise might not be as deleterious as competitive sport and current evidence justifies a less restrictive approach to leisure exercise in these patients.

**Modality of Leisure-time exercise programmes**

Patients with cardiomyopathy should not participate in exercise that requires pursuit of excellence or pressure to excel against others and involves explosive bouts of intensive exercise, apart from the exceptions as previously stated. It is necessary for clinicians to individualize exercise prescription, balancing the clinical status of the patient with the type, intensity and frequency of the physical and/or sport activity being considered. . Exercise prescription should preferentially be guided by exercise testing, aiming for a submaximal, well-tolerated level of exercise intensity.

There are specific recommendations that may reduce the arrhythmogenic risk in patients with cardiomyopathy (99-101). Patients should be fully informed of the clinical peculiarities of the disease, including the modalities of clinical presentation, and warned about the incidence of symptoms that may occur in association with exercise. Patients should be advised to start exercise sessions with a warm-up period and at the end of the session an appropriate cool-down period is also recommended.

Exercise programmes characterized by a progressive increase in intensity should be closely monitored by the physician (ideally in contact with the coach), in order to adapt the intensity, duration and frequency of training to the individual cardiac capabilities. Patient should avoid exercising in adverse environmental conditions without prior acclimatization.

In the choice of indoor activities, patients with cardiomyopathies should be encouraged to exercise in environments equipped with an automatic defibrillator and personnel trained in its use. Finally, patients with cardiomyopathy should preferentially avoid high-intensity free weight lifting, to reduce the risk of injury in the event of syncope.

**Myocarditis**

Myocarditis is defined as an inflammatory process of the myocardium, with histological evidence of myocyte degeneration and necrosis of non-ischemic origin, associated with inflammatory infiltration (105). Case series in athletes have established myocarditis as a potential cause of SCD/CA, in a range of 2% to 8% (9-11). Myocarditis may present with arrhythmia, heart failure or simulate myocardial infarction. The illness may be preceded by coryzal symptoms or diarrhea (105). Rarely, athletes may present non specific features such as fatigue which may elude the diagnosis.

Serum cardiac biomarkers for inflammation are elevated and should be measured in insuspected cases (105).

*12-lead ECG and 24-h ECG monitoring:* The ECG abnormalities include frequent and/or complex ventricular and/or supraventricular arrhythmia, ST-segment alterations, T-wave inversion and occasionally, LBBB or atrioventricular block (106). Individuals presenting with heart failure may show low QRS voltages particularly in the presence of a pericardial effusion.

*Echocardiography:* the LV may be mildly dilated with thin myocardial walls, resembling DCM, or there may be a non-dilated cavity with increased myocardial wall thickness due to myocardial oedema (107). Regional wall motion abnormalities are recognized and LV global systolic function may range from almost normal to severely depressed. The presence of severe LV dysfunction may predict severe clinical outcome (108). Concomitant pericardial effusion suggests pericardial involvement.

*Cardiovascular magnetic resonance*: CMR has excellent sensitivity for detecting myocarditis and can identify hyperemia, inflammation oedema, and/or focal scar (109,110). Furthermore, the identification of LGE may confer prognostic information, since it is a strong independent predictor of events during follow-up (109-113).

*Histology*: Endomyocardial biopsy (EMB) is considered the gold-standard for the diagnosis of myocarditis. It allows a definitive diagnosis, based on immune-histochemical testing, and the possible identification of viral genome in the cardiomyocytes through the polymerase chain reaction (PCR) analysis (114). However, EMB is not usually performed for clinical diagnosis, but in selected cases, when therapeutic strategies are debated and the result is likely to influence the treatment or prognosis of patients, such as in the case of suspected giant cell myocarditis of cardiac sarcoidosis (115).

**Risk stratification**:

There are robust data linking the presence and persistence of myocarditis to SCD/CA in young individuals. A murine model of coxsackie B3 myocarditis showed that daily exercise training increased viral titers, worsened cardiomyopathy, and increased the likelihood of death (116). In one of the first pathological surveys of SCD in a cohort of U.S. military recruits, myocarditis was reported as the most frequent disorder associated with death during strenuous physical exertion (117). More recent case series in athletes have established myocarditis as a definite risk factor for SCD (9-11,118).

The risk of sudden death does not always correlate with the severity of myocardial inflammation and serum concentrations of cardiac troponin. LV dysfunction is the major prognostic determinant of an adverse event (11,120), however, SCD/CA may occur despite normal LV function and is mostly related to tachyarrhythmias.

There is no specific test that can establish complete resolution of the inflammatory process in myocarditis. Athletes in whom the findings of acute inflammation have resolved may still harbour the risk for arrhythmias related to the resultant myocardial scar. Therefore, the interval between initial assessment and retesting before resumption of sports will vary on individual basis depending on the severity of the initial illness and morphologic sequelae.

R**ecommendations**

1. General consensus exists that athletes with diagnosis of myocarditis should be restricted from exercise programmes for a period of 3 to 6 months, according to the clinical severity and duration of the illness, LV function at onset, and extent of inflammation on the CMR. This time period is considered appropriate to ensure clinical and biological resolution of the disease (3,4, 118-120). (Class IIB; Level of Evidence C):

2. Individuals with previous myocarditis have an increased risk for recurrence and silent clinical progressionof the disease. Therefore, athletes with previous myocarditis should undergo a periodical re-assessment, particularly within the first two years. (Class IIa; Level of Evidence C):

3. It is reasonable for athletes to resume training and competition after a myocarditis if all of the following criteria are met: a) LV systolic function has returned to the normal range. b) Serum biomarkers of myocardial injury have normalized. c) Clinically relevant arrhythmias, such as frequent or complex repetitive forms of ventricular or supraventricular arrhythmias are absent on 24-h ECG monitoring and exercise test. (Class IIa; Level of Evidence C):

4. The clinical significance of persistent LGE in an asymptomatic athlete with clinically healed myocarditis is unknown, however, myocardial scar is a potential source of ventricular tachyarrhythmias (104-107). At present, it seems reasonable for these athletes to resume training and participate in competitive sport if LV function is preserved and in the absence of frequent or complex repetitive forms of ventricular or supraventricular arrhythmias during maximal exercise and on 24-h ECG monitoring (preferably during training/competition). . Asymptomatic athletes with LGE, however, should remain under annual clinical surveillance. (Class III; Level of Evidence C):

**Pericarditis**

Pericarditis is defined as an inflammatory process of the pericardium, which may also affect the sub-epicardial layers of the myocardium (121).

*Clinical presentation:* Pericarditis is usually preceded by upper respiratory or gastrointestinal symptoms, and clinical presentation may include chest pain, increased fatiguability or exertional dyspnoea. In developed countries, viruses are the most common aetiological agents for pericarditis, whereas tuberculosis is a frequent cause of pericardial disease in developing countries (121). Pericarditis and myocarditis may coexist in 20% to 30% of patients due to overlapping aetiologies. The presence of concomitant myocarditis is indicated by elevation of serum cardiac troponins and myocardial oedema on CMR. Patients with pericarditis concomitant with myocarditis (usually referred as myo-pericarditis) have potential for a higher rate of complications including LV dysfunction.

Serum cardiac biomarkers for cardiac inflammation and necrosis should be measured to exclude the possibility of myocardial involvement (122).

*12-lead ECG:* a spectrum of ECG abnormalities may be present typically including a new widespread ST-segment elevation, or PR interval depression in the acute phase.

*Echocardiography/CMR:* Often a pericardial effusion is present at the onset of the disease, with increased reflectivity and separation of the thickened pericardial layers. Athletes with pericarditis and raised biomarkers for cardiac damage should be investigated with CMR to assess the extent of myocardial involvement.

**Risk stratification**:

Individuals with pericarditis usually have an excellent prognosis with complete resolution of the pathological process (121,122). However, patients with idiopathic acute pericarditis and certain features at presentation (temperature >38°C), subacute course, large pericardial effusion, and resistance to non-steroidal anti-inflammatory drugs comprise a subset of patients with a more guarded prognosis and a greater risk for recurrence and progressing to pericardial constriction (121.122).

**Recommendations.**

1. Athletes with pericarditis should not participate in competitive sports during the acute phase. Athletes can

return to sport activity only after complete resolution of the active disease. The time period of 3 months is considered appropriate to ensure a complete clinical and biological resolution of the disease, but shorter period (at least 1 month) may be considered in selected cases with only mild clinical picture and prompt resolution (Class III; Level of Evidence C).

2. It is reasonable to return to play if the serum biomarkers have normalized, LV function is normal and there are no resting, or exercise-induced frequent/complex ventricular arrhythmias detectable on 24-h ECH monitoring or exercise ECG. (Class IIa; Level of Evidence C).

3. Athletes with concomitant myocardial involvement should be treated in accordance with the recommendations for myocarditis. (Class IIa; Level of Evidence C).

4. Asymptomatic athletes with small pericardial effusion, detected incidentally by imaging testing , but without clinical, biochemical and CMR evidence of myocardial inflammation, should not be considered as affected by myopericarditis and should not be restricted from sport participation. A periodical surveillance is however advisable (class IIa, level of evidence C)

**Cardiac classification of sport activities.**

Sports activities are here classified according to the cardiovascular changes associated with the exercise training and the long-term impact on cardiac morphology. In this regard, sport disciplines may be schematically divided in 4 major groups, i.e., skill, power, mixed and endurance (6).

Specifically, **skill sports** are disciplines with prominent technical characteristics, where the achievement is mostly based on the athlete’s neuro-muscular coordination and skill (i.e., low dynamic, low static). The cardiovascular response to regular exercise is characterized by an increase in heart rate, which may be substantial, with only modest changes in blood pressure and cardiac output. The long-term cardiac adaptation to these disciplines is characterized by minimal or no morphologic cardiac remodeling.

**Power sports** are disciplines with a prominent muscle strength component, where achievement is due to the generation of explosive muscle power (i.e., high-static exercise). The cardiovascular response to power exercise is characterized by substantial increases in blood pressure and heart rate for several, short repetitive bursts. The long-term cardiac adaptation to power disciplines is characterized by an increase in LV wall thickness and modest change in LV cavity size.

**Mixed sports** present alternate phases of work (either dynamic and/or static) and recovery periods. Typical examples are ball games and the team disciplines. The duration and intensity of work varies greatly according to the type of discipline, the role of the athlete and the trend of the game. The cardiovascular response to mixed exercise includes phasic increases in heart rate and blood pressure, which may reach near-maximum values, alternating with recovery phases, when the heart rate, blood pressure and cardiac output decrease. The long-term cardiac adaptation to mixed disciplines is characterized by an increase in LV cavity size and modest change in LV wall thickness.

**Endurance sports** are disciplines characterized by prolonged and intensive dynamic exercise (i.e., high-dynamic, often associated with high-static exercise), where the achievement is related to the athlete’s capability to attain and maintain very high cardiac output, through persistent increase in heart rate and blood pressure. Duration of the hemodynamic load is usually prolonged for 1 to 2 hours, with habitually 6 to 12 session a week in elite athletes. Cardiac remodeling with increased LV cavity size and wall thickness characterizes the cardiac adaptation to endurance disciplines. The degree of cardiac remodeling may even be marked, depending on the type of discipline, the gender, ethnic origin and body size and composition of the endurance athletes.

Legend to **Figure 1**

A schematic representation of the four different types of sport disciplines is shown. In the figure, the common hemodynamic changes and cardiac remodeling occurring as a consequence of long-term training are indicated for each type of sport.

Symbols: 🞊 indicates sport with increased risk of bodily collision.  indicates sport with intrinsic risk of serious harm or death for athlete and/or spectators in the event of syncope. .

 (*adapted and modified; ref.6*).

REFERENCES

1. Corrado D, Pelliccia A, Bjørnstad HH, Vanhees L, Biffi A, Borjesson M, Panhuyzen-Goedkoop N, Deligiannis A, Solberg E, Dugmore D, Mellwig KP, Assanelli D, Delise P, van-Buuren F, Anastasakis A, Heidbuchel H, Hoffmann E, Fagard R, Priori SG, Basso C, Arbustini E, Blomstrom-Lundqvist C, McKenna WJ, Thiene G; Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005 Mar;26(5):516-24. Epub 2005 Feb 2. Review. PubMed PMID: 15689345..
2. Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter AM, Krass MD, Maron MS, Mitten MJ, Roberts WO, Puffer JC. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update. A scientific statement from the American Heart Association council on nutrition, physical activity and metabolism. Endorsed by the American College of Cardiology Foundation. Circulation published online March 12, 2007; doi:10.1161/Circulation AHA.107.18142312.
3. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes III MNA, Cooper JR LT, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes. JACC 2015. h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 9 . 0 3 4
4. Pelliccia A, Fagard R, Bjørnstad HH, Anastassakis A, Arbustini E, Assanelli D, Biffi A, Borjesson M, Carrè F, Corrado D, Delise P, Dorwarth U, Hirth A, Heidbuchel H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A, Solberg EE, van-Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D, Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE, Oudhof J, McKenna WJ, Penco M, Priori S, Reybrouck T, Senden J, Spataro A, Thiene G; Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology; Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005 Jul;26(14):1422-45. Epub 2005 May 27. Review. PubMed PMID: 15923204.
5. Pelliccia A, Zipes DP, Maron BJ. Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol. 2008 Dec 9;52(24):1990-6. doi: 10.1016/j.jacc.2008.08.055. PubMed PMID: 19055990.
6. Pelliccia A, Caselli S, Sharma S, Basso C, Bax JJ, Corrado D, D'Andrea A, D'Ascenzi F, Di Paolo FM, Edvardsen T, Gati S, Galderisi M, Heidbuchel H, Nchimi A, Nieman K, Papadakis M, Pisicchio C, Schmied C, Popescu BA, Habib G, Grobbee D, Lancellotti P; Internal reviewers for EAPC and EACVI . European Association of Preventive Cardiology (EAPC) and European Association of Cardiovascular Imaging (EACVI) joint position statement: recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athlete's heart. Eur Heart J. 2018 Jun 1;39(21):1949-1969. doi: 10.1093/eurheartj/ehx532. PubMed PMID: 29029207.
7. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–79.
8. Gersh, B, Maron, BJ, Bonow RO et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783-e831.)
9. Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation 2009;119:1085–92.

Harmon KG, Asif IM, Maleszewski JJ, Owens DS, Prutkin JM, Salerno JC, et al. [Incidence, Cause, and Comparative Frequency of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A Decade in Review.](https://www.ncbi.nlm.nih.gov/pubmed/25977310) Circulation. 2015 Jul 7;132(1):10-9.

1. Finocchiaro G, Papadakis M, Robertus JL, Dhutia H, Steriotis AK, Tome M, et al. [Etiology of Sudden Death in Sports: Insights From a United Kingdom Regional Registry.](https://www.ncbi.nlm.nih.gov/pubmed/27151341) J Am Coll Cardiol. 2016 May 10;67(18):2108-15
2. Papadakis M, Carre F, Kervio G, Rawlins J, Panoulas VF, Chandra N, et al. The prevalence, distribution, and clinical outcomes of electrocardiographic repolarization patterns in male athletes of African/Afro-Caribbean origin. Eur Heart J. 2011;32(18):2304-13.11,12
3. Sheikh N, Papadakis M, Schnell F, Panoulas V, Malhotra A, Wilson M, Carré F, Sharma S. Clinical Profile of Athletes With Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2015 Jul;8(7):e003454. doi: 10.1161/CIRCIMAGING.114.003454
4. Calore C, Zorzi A, Corrado D. Clinical meaning of isolated increase of QRS voltages in hypertrophic cardiomyopathy versus athlete's heart. J Electrocardiol. 2015 May-Jun;48(3):373-9. doi: 10.1016/j.jelectrocard.2014.12.016.
5.
6. Pelliccia A, Di Paolo FM, Quattrini FM, Basso C, Culasso F, Popoli G, et al. Outcomes in athletes with marked ECG repolarization abnormalities. N Engl J Med. 2008;358(2):152-61). 2018 May 15. pii: CIRCULATIONAHA.118.034208. doi: 10.1161/CIRCULATIONAHA.118.034208.
7. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med. 1991;324(5):295-301.
8. Basavarajaiah S, Boraita A, Whyte G, Wilson M, Carby L, Shah A, et al. Ethnic differences in left ventricular remodeling in highly-trained athletes relevance to differentiating physiologic left ventricular hypertrophy from hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;51(23):2256-62.
9. Caselli S, Maron MS, Urbano-Moral JA, Pandian NG, Maron BJ, Pelliccia A. Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2014;114(9):1383-9.
10. Basavarajaiah S, Wilson M, Whyte G, Shah A, McKenna W, Sharma S. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol. 2008;51(10):1033-9.21. Rawlins J, Carre F, Kervio G, Papadakis M, Chandra N, Edwards C, Whyte GP,Sharma S. Ethnic differences in physiological cardiac adaptation to intense physical exercise in highly trained female athletes. Circulation 2010;121:1078–1085.21.
11. Sheikh N, Papadakis M, Carre F, Kervio G, Panoulas VF, Ghani S, Zaidi A, Gati S, Rawlins J, Wilson MG, Sharma S. Cardiac adaptation to exercise in adolescent athletes of African ethnicity: an emergent elite athletic population. Br J Sports Med. 2013 Jun;47(9):585-92. doi: 10.1136/bjsports-2012-091874.
12. Di Paolo FM, Schmied C, Zerguini YA, Junge A, Quattrini F, Culasso F, et al. The athlete's heart in adolescent Africans: an electrocardiographic and echocardiographic study. J Am Coll Cardiol. 2012;59(11):1029-36.
13. Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete's heart in women. Echocardiographic characterization of highly trained elite female athletes. JAMA. 1996;276(3):211-5.17.
14. Finocchiaro G, Dhutia H, D'Silva A, Malhotra A, Sheikh N, Narain R, Ensam B, Papatheodorou S, Tome M, Sharma R, Papadakis M, Sharma S. Role of Doppler Diastolic Parameters in Differentiating Physiological Left Ventricular Hypertrophy from Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr. 2018 May;31(5):606-613.e1. doi: 10.1016/j.echo.2017.11.022. Epub 2018 Mar 1. PubMed PMID: 29482976.
15. Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112:855– 61.
16. Maron MS, Appelbaum E, Harrigan CJ, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008;1:184 –91.
17. Sharma S, Elliott PM, Whyte G, Mahon N, Virdee MS, Mist B, et al. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol. 2000;36(3):864-70.
18. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–79.
19. Maron BJ, Pelliccia A, Spataro A, Granata M. Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes. Br Heart J. 1993;69(2):125-8.
20. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NA 3rd, Cooper LT Jr, Link MS, Maron MS. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. Circulation 2015;132:e273–e280.
21. Harmon KG, Drezner JA, Wilson MG, et al. Incidence of sudden cardiac death in athletes: a state-of-the-art review. Br J Sports Med 2014;48:1185–92.
22. Malhotra A, Dhutia H, Finocchiaro G, Gati S, Beasley I, Clift P, Cowie C, Kenny A, Mayet J, Oxborough D, Patel K, Pieles G, Rakhit D, Ramsdale D, Shapiro L, Somauroo J, Stuart G, Varnava A, Walsh J, Yousef Z, Tome M, Papadakis M, Sharma S. Outcomes of Cardiac Screening in Adolescent Soccer Players.N Engl J Med. 2018 9;379(6):524-534. doi: 10.1056/NEJMoa1714719.
23. Alpert C, Day SM, Saberi S. Sports and Exercise in Athletes with Hypertrophic Cardiomyopathy. Clin Sports Med. 2015 Jul;34(3):489-505,
24. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M, Calkins H, Estes NA, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL, Zipes DP, Berul CI, Cheng A, Law I, Loomis M, Barth C, Brandt C, Dziura J, Li F, Cannom D. Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry. Circulation. 2013 May 21;127(20):2021-30. doi: 10.1161/CIRCULATIONAHA.112.000447.
25. Maron BJ, Klues HG. Surviving competitive athletics with hypertrophic cardiomyopathy. Am J Cardiol. 1994;1;73(15):1098-104).
26. Pelliccia A, Lemme E, Maestrini V, Di Paolo FM, Pisicchio C, Di Gioia G, Caselli S. Does Sport Participation Worsen the Clinical Course of Hypertrophic Cardiomyopathy? Clinical Outcome of Hypertrophic Cardiomyopathy in Athletes. Circulation. 2018 Jan 30;137(5):531-533. doi: 10.1161/CIRCULATIONAHA.117.031725. PubMed PMID: 29378761.
27. Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS, Bongioanni S, Semsarian C, Devoto E, Musumeci B, Lai F, Yeates L, Conte MR, Rapezzi C, Boni L, Maron BJ. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014 May 1;113(9):1550-5. doi: 10.1016/j.amjcard.2014.01.435. Epub 2014 Feb 12. PMID: 2463078.
28. Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363(6):552-63.
29. Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6(3):415-22.
30. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002;105(25):2992-7.
31. Gray B, Ingles J, Semsarian C. Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. Int J Cardiol. 2011;152(2):258-9.
32. Jensen MK, Havndrup O, Christiansen M, Andersen PS, Diness B, Axelsson A, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. Circulation. 2013;127(1):48-54.
33. Vermeer AMC, Clur SB, Blom NA, Wilde AAM, Christiaans I. Penetrance of Hypertrophic Cardiomyopathy in Children Who Are Mutation Positive. J Pediatr. 2017 Sep;188:91-95. doi: 10.1016/j.jpeds.2017.03.033. Epub 2017 Apr 7. PubMed PMID: 28396031.
34. Caselli S, Pelliccia A. The electrocardiogram and the phenotypic expression of hypertrophic cardiomyopathy. Eur Heart J. 2018 Jul 13. doi: 10.1093/eurheartj/ehy403).
35. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases Eur Heart J. 2016 Jun 14;37(23):1850-8,.
36. Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Heliö T, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 May;34(19):1448-58.
37. Gavazzi A, De Maria R, Renosto G, Moro A, Borgia M, Caroli A, et al. The spectrum of left ventricular size in dilated cardiomyopathy: clinical correlates and prognostic implications. SPIC (Italian Multicenter Cardiomyopathy Study) Group. Am Heart J. 1993;125(2 Pt 1):410-22.
38. Pelliccia A, Culasso F, Di Paolo FM, Maron BJ. Physiologic left ventricular cavity dilatation in elite athletes. Ann Intern Med. 1999;130(1):23-31.
39. Finocchiaro G, Dhutia H, D’Silva A, Malhotra A, Steriotis A, Millar L, Prakash K, Narain R, Papadakis M, Sharma R, Sharma S. Effect of sex and sporting discipline on LV adaptation to exercise. JACC Cardiovasc Imaging 2016; doi: 10.1016/j.jcmg.2016.08.011.
40. Abergel E, Chatellier G, Hagege AA, Oblak A, Linhart A, Ducardonnet A, Menard J. Serial left ventricular adaptations in world-class professional cyclists: implications for disease screening and follow-up. J Am Coll Cardiol. 2004;44(1):144-9.
41. Lynne Millar, Gabriel Fernandez, Harshil Dhutia, et al. Exercise Echocardiography Has a High Sensitivity and Specificity in Differentiating Athlete’s Heart From Dilated Cardiomyopathy. Circulation. 2016;134:Abstr 15662
42. Claessen G, Schnell F, Bogaert J, Claeys M, Pattyn N, De Buck F, Dymarkowski S, Claus P, Carré F, Van Cleemput J, La Gerche A, Heidbuchel H. Exercise cardiac magnetic resonance to differentiate athlete's heart from structural heart disease. Eur Heart J Cardiovasc Imaging. 2018 Mar 26. doi: 10.1093/ehjci/jey050.
43. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013 Mar 6;309(9):896-908.
44. Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, et al. Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Circulation. 2017 May 30;135(22):2106-2115. doi: 10.1161/CIRCULATIONAHA.116.026910.
45. Spezzacatene A, Sinagra G, Merlo M, Barbati G, Graw SL, Brun F, Slavov et al. Arrhythmogenic Phenotype in Dilated Cardiomyopathy: Natural History and Predictors of Life-Threatening Arrhythmias. J Am Heart Assoc. 2015 Oct 16;4(10):e002149. doi: 10.1161/JAHA.115.002149.
46. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, van Tintelen JP, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. 2012 Jan 31;59(5):493-500.
47. Webb-Peploe KM(1), Chua TP, Harrington D, Henein MY, Gibson DG, Coats AJ. Different response of patients with idiopathic and ischaemic dilated cardiomyopathy to exercise training. Int J Cardiol. 2000 Jul 31;74(2-3):215-24.
48. 55. Haykowsky MJ, Timmons MP, Kruger C, McNeely M, Taylor DA, Clark AM. Meta-analysis of aerobic interval training on exercise capacity and systolic function in patients with heart failure and reduced ejection fractions. Am J Cardiol. 2013 May 15;111(10):1466-9. doi: 10.1016/j.amjcard.2013.01.303. Epub 2013 Feb 21.
49. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat. Rev. Cardiol. 2013;10:531–547
50. Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet 2015;386:813–25.
51. Steffel J, Kobza R, Oechslin E, Jenni R, Duru F. Electrocardiographic characteristics at initial diagnosis in patients with isolated left ventricular noncompaction Am J Cardiol. 2009;104(7):984-9. doi: 10.1016/j.amjcard.2009.05.042
52. Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart 2001;86(6):666-71.
53. Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 1990;82(2):507-13.
54. Gebhard C, Stahli BE, Greutmann M, Biaggi P, Jenni R, Tanner FC. Reduced left ventricular compacta thickness: a novel echocardiographic criterion for non-compaction cardiomyopathy. Journal of the American Society of Echocardiography: 2012;25(10):1050-7.
55. Caselli S, Attenhofer Jost C.H., Jenni R., Pelliccia A. Left ventricular noncompaction diagnosis and management relevant to pre-participation screening of athletes, Am. J. Cardiol. 116 (2015) 801–808
56. Caselli S, Ferreira D, Kanawati E, Di Paolo F, Pisicchio C, Attenhofer Jost C, Spataro A, Jenni R, Pelliccia A. Prominent left ventricular trabeculations in competitive athletes: A proposal for risk stratification and management. Int J Cardiol. 2016 Nov 15;223:590-595. doi: 10.1016/j.ijcard.2016.08.272.
57. Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH, Watkins H, Neubauer S. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46:101–105. doi: 10.1016/j.jacc.2005.03.045
58. Zemrak F, Ahlman MA, Captur G, et al. The relationship of left ventricular trabeculation to ventricular function and structure over a 9.5-year follow-up: the MESA study. J Am Coll Cardiol 2014;64:1971–80.
59. Kohli SK, Pantazis AA, Shah JS, Adeyemi B, Jackson G, McKenna WJ, Sharma S, Elliott PM. Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria? Eur Heart J. 2008 Jan;29(1):89-95. Epub 2007 Nov 9
60. Corrado D1, Link MS1, Calkins HN. Arrhythmogenic Right Ventricular Cardiomyopathy. N Engl J Med. 2017 Jan 5;376(1):61-72. doi: 10.1056/NEJMra1509267.
61. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318:129–33. http://dx.doi.org/10.1056/NEJM198801213180301).
62. Bagnall RD, Weintraub RG, Ingles J, Duflou J, Yeates L, Lam L, et al. A Prospective Study of Sudden Cardiac Death among Children and Young Adults. N Engl J Med. 2016;374(25):2441-52.
63. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533–1541. doi: 10.1161/CIRCULATIONAHA.108.840827.
64. Nasir K, Bomma C, Tandri H, Roguin A, Dalal D, Prakasa K, et al. Electrocardiographic features of arrhythmogenic right ventricular dysplasia/cardiomyopathy according to disease severity: a need to broaden diagnostic criteria. Circulation. 2004 Sep 21;110(12):1527-34
65. Bauce B, Frigo G, Benini G, Michieli P, Basso C, Folino AF, et al. Differences and similarities between arrhythmogenic right ventricular cardiomyopathy and athlete's heart adaptations. Br J Sports Med. 2010 Feb;44(2):148-54. doi: 10.1136/bjsm.2007.042853.
66. Perazzolo Marra M, Rizzo S, Bauce B, De Lazzari M, Pilichou K, Corrado D, Thiene G, Iliceto S, Basso C. Arrhythmogenic right ventricular cardiomyopathy. Contribution of cardiac magnetic resonance imaging to the diagnosis. Herz. 2015 Jun;40(4):600-6. doi: 10.1007/s00059-015-4228-0. Review. PubMed PMID: 26077775.
67. Zaidi A, Ghani S, Sharma R, Oxborough D, Panoulas VF, Sheikh N, et al. Physiological right ventricular adaptation in elite athletes of African and Afro-Caribbean origin. Circulation. 2013 Apr 30;127(17):1783-92. doi: 10.1161/CIRCULATIONAHA.112.000270. Epub 2013 Mar 28.
68. D'Ascenzi F, Pisicchio C, Caselli S, Di Paolo FM, Spataro A, Pelliccia A. RV Remodeling in Olympic Athletes. JACC Cardiovasc Imaging. 2016 Aug 11. pii: S1936-878X(16)30467-3. doi: 10.1016/j.jcmg.2016.03.017.
69. Quarta G, Muir A, Pantazis A, Syrris P, Gehmlich K, Garcia-Pavia P, Ward D, Sen-Chowdhry S, Elliott PM, McKenna WJ. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised Task Force Criteria. Circulation 2011; 123: 2701-9.
70. Kapplinger JD, Landstrom AP, Salisbury BA, Callis TE, Pollevick GD, Tester DJ, Cox MG, Bhuiyan Z, Bikker H, Wiesfeld AC, Hauer RN, van Tintelen JP, Jongbloed JD, Calkins H, Judge DP, Wilde AA, Ackerman MJ.. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol 2011; 57: 2317-27]
71. Calkins H, Corrado D, Marcus F. Risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation. 2017;136:2068-2082
72. Maupain C, Badenco N, Pousset F, Waintrub X, Duthoit G, Chastre T, Himbert C, Herbert J, Frank R, Hidden-Lucet FGandjbakch. Cardiomyopathy/Dysplasia without an implantable cardioverter-defibrillator. JACC Clinical Electrophysiology. 2018;4: 757-768.
73. Kirchhof P, Fabritz L, Zwiener M, Witt H, Schäfers M, Zellerhoff S, Paul M, Athai T, Hiller KH, Baba HA, Breithardt G, Ruiz P, Wichter T, Levkau B. Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation. 2006;114:1799–806. http://dx.doi.org/10.1161/ CIRCULATIONAHA.106.624502.
74. Benito B, Gay-Jordi G, Serrano-Mollar A, Guasch E, Shi Y, Tardif JC, Brugada J, Nattel S, Mont L. Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. https://doi.org/10.1161/CIRCULATIONAHA.110.938282 Circulation. 2010;CIRCULATIONAHA.110.938282
75. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, Tedford RJ, Judge DP, Calkins H. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62: 1290–7. http://dx.doi.org/10.1016/j.jacc.2013.06.033.
76. Saberniak J, Hasselberg NE, Borgquist R, Platonov PG, Sarvari SI, Smith HJ, Ribe M, Holst AG, Edvardsen T, Haugaa KH. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail 2014;16:1337–1344.
77. Ruwald AC, Marcus F, Estes NA, Link M, McNitt S, Polonsky B, et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2015.
78. Heidbüchel H, Hoogsteen J, Fagard R, Vanhees L, Ector H, Willems R, Van Lierde J. High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiologic study in risk stratification. Eur Heart J. 2003 Aug;24(16):1473-80. PubMed PMID: 12919770.
79. Sawant AC, Bhonsale A, te Riele AS, Tichnell C, Murray B, Russell SD, et al. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc. 2014;3(6):e001471.
80. La Gerche A, Robberecht C, Kuiperi C, Nuyens D, Willems R, de Ravel T, Matthijs G, Heidbüchel H. Lower than expected desmosomal gene mutation prevalence in endurance athletes with complex ventricular arrhythmias of right ventricular origin. Heart . 2010 Aug;96(16):1268-74. doi: 10.1136/hrt.2009.189621. Epub 2010 Jun 4.
81. La Gerche A, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J, et al. . Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes. Eur Heart J. 2012 Apr;33(8):998-1006. doi: 10.1093/eurheartj/ehr397.
82. Schnell F, Riding N, O'Hanlon R, Axel Lentz P, Donal E, Kervio G, et al. Recognition and significance of pathological T-wave inversions in athletes. Circulation. 2015;131(2):165-73.
83. Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, La Gerche A, Ackerman MJ, Borjesson M, Salerno JC, Asif IM, Owens DS, Chung EH, Emery MS, Froelicher VF, Heidbuchel H, Adamuz C, Asplund CA, Cohen G, Harmon KG, Marek JC, Molossi S, Niebauer J, Pelto HF, Perez MV, Riding NR, Saarel T, Schmied CM, Shipon DM, Stein R, Vetter VL, Pelliccia A, Corrado D. International Recommendations for Electrocardiographic Interpretation in Athletes. J Am Coll Cardiol. 2017 Feb 28;69(8):1057-1075. doi: 10.1016/j.jacc.2017.01.015. Review. PubMed PMID: 28231933
84. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M, Calkins H, Estes NAM, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL, Zipes DP, Berul CI, Cheng A, Jordaens L, Law I, Loomis M, Willems R, Barth C, Broos K, Brandt C, Dziura J, Li F, Simone L, Vandenberghe K, Cannom D. Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Long-Term Results of a Prospective Multinational Registry. Circulation. 2017 Jun 6;135(23):2310-2312. doi: 10.1161/CIRCULATIONAHA.117.027828. PMID: 28584032
85. Heidbuchel H. Implantable cardioverter defibrillator therapy in athletes. Cardiol Clin 2007;25:467–482.
86. Heidbuchel H, Carré F. Exercise and competitive sports in patients with an implantable cardioverter-defibrillator. Eur Heart J. 2014 Nov 21;35(44):3097-102. doi: 10.1093/eurheartj/ehu130. Epub 2014 Apr 8. Review. PubMed PMID: 24713647.
87. Heidbuchel H, Corrado D, Biffi A, Hoffmann E, Panhuyzen-Goedkoop N, Hoogsteen J, Delise P, Hoff PI, Pelliccia A. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions Part II: ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil 2006;13: 676–686..
88. Maron BJ, Chaitman BR, Ackerman MJ, Bayes de Luna A, Corrado D, Crosson JE, Deal BJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004;109:2807-2816.
89. Pelliccia A, and Quattrini F. Leisure-time physical activity and sport participation in patients with Cardiomyopathies. in Arrhythmias in Athletes. Corrado D, Basso C, Thiene G Editors. Cardiac Electrophysiology Clinics 2013; Vol 5, no 1, pages 65-72
90. Saberi S, Wheeler M, Bragg-Gresham J, Hornsby W, Agarwal PP, Attili A, et al. Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA. 2017 Apr 4;317(13):1349-1357. doi: 10.1001/jama.2017.2503
91. Klempfner R, Kamerman T, Schwammenthal E, Nahshon A, Hay I, Goldenberg I, Dov F, Arad M. Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center. Eur J Prev Cardiol. 2015 Jan;22(1):13-9. doi: 10.1177/2047487313501277. Epub 2013 Aug 8. PubMed PMID: 23928567.
92. Olivotto I1, Maron BJ, Tomberli B, Appelbaum E, Salton C, Haas TS, Gibson CM, Nistri S, Servettini E, Chan RH, Udelson JE, Lesser JR, Cecchi F, Manning WJ, Maron MS Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Jul 30;62(5):449-57. doi: 10.1016/j.jacc.2013.03.062. Epub 2013 Apr 30.
93. Sinagra G, Anzini M, Pereira NL, Bussani R, Finocchiaro G, Bartunek J, Merlo M. Myocarditis in Clinical Practice. Mayo Clin Proc. 2016 Sep;91(9):1256-66.
94. Morgera T, Di Lenarda A, Dreas L, Pinamonti B, Humar F, Bussani R, et al. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. Am Heart J. 1992;124(2):455-67.
95. Pinamonti B, Alberti E, Cigalotto A, Dreas L, Salvi A, Silvestri F, et al. Echocardiographic findings in myocarditis. Am J Cardiol. 1988;62(4):285-91.
96. Caforio AL, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, Ramondo A, Carturan E, Iliceto S, Thiene G, Daliento L. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007 Jun;28(11):1326-33.
97. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. Journal of the American College of Cardiology 2009;53(17):1475-87.
98. Schnell F, Claessen G, La Gerche A, Bogaert J, Lentz PA, Claus P, Mabo P, Carré F, Heidbuchel H. Subepicardial delayed gadolinium enhancement in asymptomatic athletes: let sleeping dogs lie? Br J Sports Med. 2016 Jan;50(2):111-7. doi: 10.1136/bjsports-2014-094546..
99. Mewton N, Dernis A, Bresson D, Zouaghi O, Croisille P, Flocard E, et al. Myocardial biomarkers and delayed enhanced cardiac magnetic resonance relationship in clinically suspected myocarditis and insight on clinical outcome. J Cardiovasc Med (Hagerstown). 2015 Oct;16(10):696-703. doi: 10.2459/JCM.0000000000000024.
100. van de Schoor FR, Aengevaeren VL, Hopman MT, et al. Myocardial Fibrosis in Athletes. Mayo Clin Proc. 2016 Nov;91(11):1617-1631. doi: 10.1016/j.mayocp.2016.07.012.
101.
102.
103. Kiel RJ, Smith FE, Chason J, Khatib R,Reyes MP. Coxsackievirus B3 myocarditis in C3H/HeJ mice: description of an inbred model and the effect of exercise on virulence. Eur J Epidemiol.1989;5:348–50.
104. Phillips M, Robinowitz M, Higgins JR, Boran KJ,Reed T, Virmani R. Sudden cardiac death in Air Force recruits: a 20-year review. JAMA. 1986;256:2696–9.
105. Bohm P, Scharhag J and Meyer T. Data from a nationwide registry on sports-related sudden cardiac deaths in Germany. European Journal of Preventive Cardiology 2016, Vol. 23(6) 649–656
106. Anzini M, Merlo M, Sabbadini G, et al. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. Circulation. 2013;128(22):2384-2394.
107. Magnani JW, Danik HJS, Dec GW Jr, DiSalvo TG. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J. 2006;151(2):463-470.
108. Imazio M; Gaita F; LeWinter M, Evaluation and Treatment of Pericarditis A Systematic Review. JAMA. 2015;314(14):1498-1506. doi:10.1001/jama.2015.12763
109. Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. Circulation. 2010 Feb 23;121(7):916-28.